The pathway leading to the telltale sign of ALS, protein aggregation in the cytoplasm of motor neurons, has been revealed. Researchers from the University of California – San Diego (CA, USA) have ...
Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for only two to five years after being diagnosed, according to the Centers for ...
Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for only two to five years after being diagnosed, according to the Centers for ...
Clene (CLNN) announced that it recently received written guidance from the Division of Neurology 1, DN1, of the U.S. Food and Drug Administration regarding a potential accelerated approval pathway for ...
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder marked by progressive degeneration of upper and lower motor neurons, resulting in paralysis and death typically within 3-5 ...
SEOUL, South Korea, Sept. 17, 2025 /PRNewswire/ -- CorestemChemon Inc. (KOSDAQ: 166480) announced today that it has presented key findings from the Phase 3 ALSummit trial of Neuronata-R® ...
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that causes progressive muscle weakness. A research team at Tohoku University and Keio University has uncovered a unifying ...
FDA recommends that Clene (CLNN) leverage additional Neurofilament Light (NfL) data from its three Expanded Access Protocols (EAPs) and the HEALEY ALS Platform Trial to support earlier presented ...
Pictured are nuclei of induced pluripotent stem cell (iPSC)-derived motor neurons stained for contrast. The nucleus on the left has been treated with DMSO (control) and appears mostly blue. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results